The Truth Is Out There

Posts tagged ‘health’

USDA/NIAID-Funded Scientists Build Chimeric Bird Flu Viruses with 100% Mortality in Mammals: Journal ‘npj Vaccines’


Gov’t finances creation of lethal avian influenza Frankenviruses in Nebraska.

A newly released npj Vaccines study confirms that U.S. government–funded researchers constructed hybrid influenza viruses in the lab and used them to trigger complete mortality in animal experiments, while framing the work under vaccine development.

The experiment, titled “Dual-Route H5N1 Vaccination Induces Systemic and Mucosal Immunity in Murine and Bovine Models,” was conducted by University of Nebraska–Lincoln scientists Joshua Wiggins, Adthakorn Madapong, and Eric A. Weaver.

You can contact the university’s Center for Virology here and the School of Biological Sciences here.

The creation of deadly chimeric pathogens was financed by the U.S. Department of Agriculture (USDA) and the National Institute of Allergy and Infectious Diseases (NIAID).

The study explicitly states:

“This research was supported by the U.S. Department of Agriculture, National Institute of Food and Agriculture, Agriculture and Food Research Initiative (Grant Nos. 2020 -06448 and 2024 -08723 to E.A.W.), and by the National Institutes of Health –NIAID (Grant No. 1R01AI147109 to E.A.W.).”

You can contact NIAID here, the NIH hereHHS here, and the USDA here to voice opposition to taxpayer-funded chimeric research on pandemic pathogens—particularly after Congress, the White House, the Department of Energy, the FBI, the CIA, and Germany’s Federal Intelligence Service (BND) all acknowledged that the deadly COVID-19 pandemic was “likely” the result of a laboratory incident involving genetically modified pathogens.


Lab-Built ‘Chimeric’ Influenza Viruses

The researchers say they constructed the hybrid bird flu pathogens using reverse genetics.

That means the scientists assembled the viruses from scratch by inserting their genetic sequences into plasmids and introducing them into cells, which then are said to produce a fully formed infectious virus.

The paper states:

“A BSL-2 compliant reverse genetic (rg) system was used to produce” H5N1 Influenza A virus strains.”

And details how they were assembled:

“Six (PB1, PB2, PA, NP, M, and NS) IAV gene segments from the PR/8/34 H1N1 laboratory strain were cloned individually into the pHW2000 vector. Separately, the neuraminidase (N) gene and hemagglutinin (H) gene without the highly pathogenic multibasic cleavage site from each strain were synthesized and cloned into the same pHW2000 vector.”

This is a genetic recombination system:

  • Internal genes from a lab strain (PR/8/34)
  • Surface genes (H5N1) inserted
  • Entire virus rebuilt from plasmids

That is a chimeric influenza construct—a hybrid assembled in the lab.

Engineered Pathogens Cause Lethal Disease

Even with deliberate modification of a known virulence element:

“hemagglutinin… without the highly pathogenic multibasic cleavage site”

—the viruses remained lethal.

100% Mortality in Mammals

The outcome in animals exposed to these engineered viruses is stated plainly:

“unvaccinated DPBS controls exhibited progressive weight loss… reaching 25%… requiring euthanasia.”

And:

“all control mice succumbed to infection.”

In contrast to any other framing, this is the core biological result:

  • Rapid disease progression
  • Severe physiological decline
  • Complete mortality in unprotected animals

‘Lethal Challenge’ With Lab-Constructed Viruses

The study confirms the conditions:

“mice were challenged with lethal H5N1 reverse genetics (rg)-A/Vietnam/1203/2004(Vietnam/1203/04) or rg-A/Bovine/Ohio/B24-OSU-439/2024 (Bovine/24).”

The animals were intentionally infected with engineered lethal influenza hybrid constructs.

What the Study Actually Demonstrates

Stripped of framing, the paper shows:

  • U.S. government–funded researchers
  • Constructed hybrid (chimeric) influenza viruses from genetic components
  • Used those constructs to induce lethal disease in mammals
  • Achieved 100% mortality in controls under experimental infection

The work is presented under the justification of vaccine research.

But the underlying capability demonstrated is the intentional assembly and use of bioengineered influenza pathogens capable of killing animals.

Bottom Line

NIAID- and USDA-funded researchers say they built lab-assembled bird flu viruses by combining genetic components from multiple strains.

Then they used those engineered pathogens to infect mammals, producing rapid disease and 100% death.

Pfizer Reboots Lyme Vaccine Linked to Lyme-Disease-Like Autoimmune Arthritis and Class Action Lawsuits


Forces your body to flood bloodstream with antibody proteins that ticks consume during feeding.

Pfizer and Valneva have advanced their experimental Lyme disease vaccine, PF-07307405 (LB6V, formerly VLA15), using the same core biological mechanism that sparked autoimmune arthritis concerns, lawsuits, and the eventual withdrawal of the only previous Lyme vaccine, LYMErix.

The jab works by forcing the body to produce antibodies against a bacterial protein that resembles a protein found in your own joint tissue, meaning those antibodies may also recognize similar structures in your joints and trigger an immune response there.

That means a mechanism previously tied to immune responses against joint tissue—producing Lyme-like symptoms—is now being brought back and positioned for broad public rollout.

Moreover, current data tracks antibody levels in the bloodstream over months, but does not map where those antibodies distribute in human tissues or how repeated boosting affects immune activity over the long term.


The Mechanism Activates Only After a Tick Bites

The vaccine is built to force the body to produce large quantities of anti-OspA IgG antibodies that circulate in the bloodstream.

Those antibodies remain inactive until a tick begins feeding.

At that point, the process engages.

The companies describe it:

“As the tick feeds on the vaccinated person, these antibodies are ingested by the tick as part of its blood meal. Binding of vaccine-induced antibodies to OspA on Borrelia inside the tick inhibits the bacterium’s ability to leave the tick.”

The antibodies are produced in the human body, but their intended function occurs after they are consumed by the tick.

The activity takes place inside the parasite.

Same OspA Design Behind LYMErix

The approach mirrors the OspA-based strategy used in LYMErix, introduced in 1998 and withdrawn in 2002 after widespread controversy.

At the center of that controversy was molecular mimicry.

The OspA protein contains regions that resemble a human protein known as LFA-1 (leukocyte function-associated antigen-1), which is present on immune cells and in joint tissue. A 1998 Science paper (Gross et al.) identified this overlap, showing that immune responses to OspA could also recognize similar structures on human LFA-1.

In patients with treatment-resistant Lyme arthritis, immune responses directed at OspA were observed to cross-react with LFA-1, raising the possibility that antibodies generated against the bacterial protein could also interact with joint tissue.


Autoimmune Arthritis Concerns Drove Lawsuits and Withdrawal

The cross-reactivity concern—antibodies recognizing both bacterial targets and structurally similar human proteins—became a central issue.

Reports of adverse outcomes, combined with media attention and legal action, intensified scrutiny around the vaccine.

A January 2001 New York Times publication explained:

A panel of U.S. experts is set to hear arguments Wednesday about whether a vaccine against Lyme disease may be linked to rare cases of arthritis, a charge the product maker has disputed.

GlaxoSmithKline Plc, the vaccine manufacturer and the world’s largest drug company, said it plans to present information on patients’ experiences since the product debuted under the brand name LYMErix in January 1999.

The Food and Drug Administration (FDA) is holding the public meeting to review the product’s safety and update the advisory panel on complaints that LYMErix may be linked to an untreatable type of arthritis.

Some scientists theorize that a protein, OspA, in the vaccine may trigger arthritis in patients with a genetic sensitivity to the condition. An estimated 30 percent of people have the gene suspected to put them at risk.

Lawyers have filed suit against GlaxoSmithKline, charging that the company should have warned that some people who receive the vaccine may experience arthritis that resists treatment.

LYMErix was ultimately withdrawn from the market.

While “poor sales” was cited publicly, later analyses pointed to the convergence of safety concerns and litigation as the force behind the collapse.

A February 2011 Clinical Infectious Diseases publication explains:

“Because of the hypothesis of molecular mimicry and autoimmune responses to the vaccine, anti-vaccine sentiment and class action lawsuits, a complicated vaccine administration schedule, diminishing physician support for the vaccine, and low public demand for the vaccine; the manufacturer voluntarily terminated vaccine production and marketing of the vaccine in 2002.”

The Vaccine Is Built to Induce the Same Immune Response Behind Lyme Arthritis

Lyme disease is known to produce an immune-driven arthritis in some patients—joint swelling, pain, and inflammation that can persist even after the bacteria are no longer detectable.

At that stage, the symptoms are not being driven by infection.

They are being driven by the immune response itself.

That same category of immune activity sits at the center of the vaccine’s design.

The shot is designed to force the body to generate high levels of anti-OspA antibodies against a bacterial protein that has been shown to share structural similarity with human LFA-1—a protein present in joint tissue.

That overlap places the immune response and the target in the same biological context as Lyme-related joint inflammation.

The result is a direct convergence: the vaccine is engineered to induce the same type of immune response associated with joint inflammation in Lyme disease.

This is the same biological interaction that raised concern during the LYMErix era.

Same Mechanism, Sustained Through Repeated Dosing

The current Pfizer candidate expands the design across six Borrelia serotypes.

Its function depends on maintaining elevated antibody levels in circulation, which decline over time based on earlier clinical data.

Booster doses are used to restore those levels, creating repeated cycles of immune activation centered on the same anti-OspA response.

Each cycle reinforces the same antibody pathway tied to the original controversy.

Autoimmune Monitoring Built Into Trials

A Phase 2 booster study published in The Lancet Infectious Diseases monitored participants for autoimmune and neuroinflammatory conditions—the same category of concern associated with the earlier vaccine.

Reported events were assessed by investigators—who worked for Pfizer—as unrelated to the vaccine.

The underlying interaction of antibodies targeting a bacterial protein with structural similarity to human tissue remains unchanged.

Critical Data Gap the Companies Aren’t Addressing

Current trials primarily track antibody levels in the bloodstream over limited time windows.

They have not mapped in detail where these anti-OspA antibodies distribute in human tissues, especially in joints and other sites where LFA-1 is expressed.

There is also no multi-year human data showing how repeated annual boosting affects immune activity over extended periods.

In practical terms, antibody levels in the blood are measured, but tissue-level behavior and long-term immune effects under repeated stimulation are not directly tracked.

This is the same blind spot that existed during the LYMErix era, before concerns around immune-mediated joint effects escalated into broader scrutiny.

Now Pfizer and Valneva are advancing the same mechanism, expanded across more strains and structured around repeated dosing, while those same unanswered questions remain.

Pfizer Felony

Pfizer is a massively criminal enterprise, repeatedly convicted and fined billions for systemic illegal activities, including off-label marketing, safety violations, bribery, price-fixing, and healthcare fraud.

With over $10 billion in penalties since 2002, Pfizer has a proven pattern of habitual corporate crime driven by profit at the expense of public health and legality.

Pfizer has pleaded guilty to felony criminal charges, including in 2009 when its subsidiary Pharmacia & Upjohn pleaded guilty to a felony count of misbranding pharmaceuticals.

The company agreed to pay a record $2.3 billion criminal and civil settlement for illegal marketing and healthcare fraud, confirming its status as a convicted corporate felon.

That same company is now rolling out a new Lyme vaccine built on the same mechanism that previously ignited safety concerns, lawsuits, and a full market collapse.

Bottom Line

Pfizer’s Lyme vaccine revives the same OspA antibody mechanism that triggered autoimmune arthritis concerns, lawsuits, and market collapse.

It is built around inducing the same category of immune response associated with Lyme-related joint inflammation.

That response is reinforced through repeated dosing.

And the mechanism itself is designed to activate only after antibodies produced in the bloodstream are consumed by a feeding tick.

Washington Joins WHO Pandemic Orchestration and Surveillance Network ‘GOARN’—Citing Bird Flu as Justification


Follows California, Illinois, Colorado, and New York City’s entry into same transnational WHO outbreak coordination system.

Governor Bob Ferguson announced this month that Washington State is now part of the World Health Organization Global Outbreak and Response Network (GOARN), an international syndicate of “public health agencies, national governments, academic centers, laboratories, and response organizations focused on rapidly detecting and responding to public health emergencies,” according to a press release from the Washington State Nurses Association (WSNA).

Washington joins California, Illinois, Colorado, and New York City by entering GOARN.

According to WSNA, Washington’s public health leaders will fall in line with the WHO’s:

  • global outbreak early-warning alerts, meaning real-time surveillance tied into an international detection system
  • technical collaboration and support during major public health events, meaning coordinated response across jurisdictions
  • international training, exercises, and best-practice exchanges, meaning standardized response protocols
  • and coordinated outbreak response support, meaning integrated deployment during declared emergencies.

Congress has already confirmed that the WHO’s response to the COVID-19 pandemic “was an abject failure” and that the WHO’s “newest effort to solve the problems exacerbated by the COVID-19 pandemic — via a “Pandemic Treaty” — may harm the United States.”

This means Washington’s decision comes despite federal findings that the WHO mismanaged the last pandemic and is advancing new agreements that could expand its influence over future responses.

You can contact Gov. Ferguson’s office here to voice your opposition to Washington’s integration into a WHO-linked outbreak surveillance and response system and demand accountability for aligning state public health infrastructure with failed global coordination mechanisms.

Washington State Governor Bob Ferguson (Governor.WA.gov)

In the governor’s press release, Washington State Secretary of Health Dennis Worsham cited avian influenza (“bird flu”) in justifying the move:

“Disease outbreaks don’t stop at state or national borders, and our ability to protect people in Washington shouldn’t either,” Washington State Secretary of Health Dennis Worsham said. “Joining GOARN ensures we maintain access to critical global outbreak intelligence and stay connected to leading public health experts, even as federal relationships change. We’re not waiting for the next threat — we’re preparing for it. From COVID-19 to rising measles cases and avian influenza, we’ve seen how quickly diseases can spread. Through GOARN, we can detect risks earlier, respond faster and better protect people in our communities — while also contributing Washington’s expertise to global response efforts.”

The development comes as bird flu is being framed internationally as an imminent threat while laboratory manipulation of the virus continues, vaccines are developed in parallel, and global, federal, and state systems are aligned to respond.

This is the same sequence of surveillance, lab work, and countermeasure rollout that preceded the COVID-19 pandemic.

HHS Funds Gain-of-Function Influenza–COVID ‘Frankenvirus’ Combining Influenza Entry Machinery With SARS-CoV-2 Human Cell–Binding Domain


HHS-backed research produced chimeric influenza viruses carrying SARS-CoV-2’s ACE2-binding interface—introducing a higher-affinity human receptor-binding mechanism into an influenza pathogen.

HHS-funded researchers are claiming to have engineered influenza-based chimeric “Frankenstein” viruses that combine influenza’s hemagglutinin (HA) with the SARS-CoV-2 receptor-binding domain (RBD)—a high-affinity human ACE2-binding interface.

Introducing a fundamentally different and stronger human cell–binding mechanism into an influenza viral system is a modification that fits longstanding U.S. gain-of-function definitions involving altered receptor usage and host range.

A December 2025 bioRxiv preprint confirms the work, supported in part by the National Institutes of Health (NIH)—an agency within the U.S. Department of Health and Human Services (HHS)—was funded under grant P01-AI165075:

“This work was funded by… National Institutes of Health… P01-AI165075”

and involved replacing influenza’s native HA gene with the SARS-CoV-2 RBD while producing virus particles coated with HA in the laboratory, resulting in viral constructs that physically contain both influenza’s entry protein and the SARS-CoV-2 optimized human cell–binding interface.

The study was conducted by Jonathan Munro, Diana Melnyk, Madeeha Afzal, Lisa Schimanski, Alexander A. Cohen, Jennifer R. Keeffe, Pamela J. Bjorkman, William S. James, Alain R. Townsend, and Tiong Kit Tan, with affiliations including the University of Oxford’s Weatherall Institute of Molecular Medicine and Sir William Dunn School of Pathology (here), the Chinese Academy of Medical Sciences–Oxford Institute (here), and the California Institute of Technology (here).

The head of HHS is Secretary Robert F. Kennedy Jr., while NIH is led by Director Jay Bhattacharya and NIAID is headed by Director Jeffery Taubenberger.

You can contact NIAID here, the NIH here, and HHS here to voice opposition to taxpayer-funded chimeric research on pandemic pathogens—particularly after Congress, the White House, the Department of Energy, the FBI, the CIA, and Germany’s Federal Intelligence Service (BND) all acknowledged that the deadly COVID-19 pandemic was “likely” the result of a laboratory incident involving GOF.

Meanwhile, President Donald Trump recently signed legislation into law allocating at least $5.5 billion in taxpayer funding for a future influenza pandemic.

At the same time, the Trump administration has advanced a $500 million “next-generation, gold-standard” combination influenza-COVID vaccine platform—positioning federal agencies to simultaneously fund the development of pandemic-capable influenza-COVID pathogens while building the mass vaccination infrastructure designed to respond to the very outbreak those systems could enable.


Engineered Virus Introduces High-Affinity Human Receptor Binding Into Influenza Backbone

The study explicitly confirms that influenza’s native receptor-binding gene was removed and replaced:

“the native haemagglutinin (HA) sequence is replaced with the coding sequence of… the receptor-binding domain (RBD) of the… SARS-CoV-2”

Influenza viruses naturally infect human cells using hemagglutinin, which binds sialic acid receptors with relatively low individual affinity and relies on multivalent interactions across many HA proteins.

By contrast, the SARS-CoV-2 receptor-binding domain binds directly to the human ACE2 receptor through a high-affinity protein–protein interaction, enabling efficient attachment to human airway cells.

By inserting the SARS-CoV-2 RBD into an influenza backbone, the researchers introduced a human ACE2-binding interface into a virus that does not naturally use that receptor system.

Chimeric Particles Combine Influenza HA and SARS-CoV-2 RBD

The study explicitly states that the influenza virus was genetically modified by replacing its HA coding sequence with the SARS-CoV-2 receptor-binding domain:

“we replaced the native HA coding sequence”

and:

“In this study, we describe the generation of a non-replicating pseudotyped influenza A virus (S-FLU), where the native haemagglutinin (HA) sequence is replaced with the coding sequence of either a membrane-anchored form (TM) or secretory form (Sec) of the receptor-binding domain (RBD) of the ancestral SARS-CoV-2 Wuhan (S-RBD Wuhan).”

At the same time, the study makes clear that HA function is not eliminated at the particle level, but instead supplied externally:

“Inactivation of the native haemagglutinin (HA) signal sequence means that S-FLU can only replicate in cell lines transfected to express HA that provide the surface protein for budding viral particles.”

The authors also confirm that the resulting engineered virus retains the ability to enter cells:

“Notably, S-FLU exhibits the capacity to infect host cells but is replication-incompetent.”

Study Confirms Infection & Expression of SARS-CoV-2 Binding Domain

The researchers confirmed that the engineered virus successfully infected cells and expressed the inserted RBD:

“both S-RBD-TM and S-RBD-Sec led to expression of RBD in the infected cells”

This demonstrates that the chimeric virus delivers and expresses the SARS-CoV-2 receptor-binding domain inside host cells following infection.

Bottom Line

HHS-funded researchers say they have engineered influenza-based viruses that combine influenza’s hemagglutinin (HA) with the SARS-CoV-2 receptor-binding domain (RBD).

They replaced the HA gene with the RBD.

But they still produced virus particles coated with HA.

The result is a chimera that physically carries both influenza’s entry machinery and a high-affinity human ACE2-binding interface.

The study confirms these viruses infect cells and express the RBD.

That is a direct change in receptor usage, consistent with longstanding U.S. gain-of-function definitions.

The work was funded under NIH grant P01-AI165075.

At the same time, the federal government is allocating at least $5.5 billion for an influenza pandemic and advancing a $500 million influenza-COVID vaccine platform—building both the engineered viral systems and the mass-response infrastructure in parallel.

Hawaii Bill Shields State-Directed Medical Interventions Like Vaccines From Lawsuits: HB1898


After state’s vaccine passport era, Hawaii lawmakers want to give Department of Health final authority over medical decisions while blocking lawsuits and discipline against those who enforce them.

Hawaii lawmakers are advancing a bill that gives the state’s Department of Health decisive control over which vaccines and preventive services count as medically valid—and then protects anyone who carries them out from nearly all legal consequences.

House Bill 1898 (S.D. 1) creates immunity from civil lawsuits, criminal liability, and professional discipline for providers who follow DOH recommendations on “clinical preventive services.”

If harm occurs later, the main legal question becomes whether the provider obeyed state guidance.

During the next outbreak or pandemic, when the DOH again requires vaccination to work, attend school, travel, or participate in society, anyone injured by the shot could have no one to hold accountable—because the bill grants legal immunity to every doctor, pharmacist, and facility that simply followed state orders.

Watchdog groups actively monitoring the CDC’s Vaccine Adverse Event Reporting System (VAERS) data confirm 2.7 million adverse events have been linked to vaccines since 1990 (~204 adverse events per day)—though a Harvard Pilgrim Health Care report found that fewer than 1% of adverse events are ever reported, suggesting the true number could be in the hundreds of millions (~20,360 adverse events per day).

The accountability-erasing bill is backed by Democrat lawmakers, including Reps. Scot MatayoshiTerez AmatoDella Au BelattiLuke EvslinTina GrandinettiLisa MartenDaynette MorikawaJackson SayamaGregg TakayamaAdrian Tam, and David Tarnas.

HB1898 is in the final stage in the Senate, one step away from passage before being sent to the Governor.

You can contact Hawaii senators here and voice your opinion of the bill and how they should vote on it.

Health-Freedom Principles Violated by the Bill

The bill directly undermines several longstanding health-freedom principles:

  1. Bodily Autonomy and Informed Consent: Full insurance coverage and legal protection are available only for DOH-approved interventions. Families who prefer a different schedule or approach must pay out of pocket for alternatives that carry no such protections.
  2. Medical Accountability: The bill states that “[n]o person shall be subject to civil or criminal liability or professional disciplinary action” for providing services in accordance with DOH recommendations. Professional organizations, hospitals, and licensing boards are barred from disciplining, suspending, or penalizing providers who follow the state line.
  3. Independent Medical Judgment: Doctors who disagree with the DOH’s final decision on immunizations risk professional repercussions, while those who comply are shielded.
  4. Parental Rights in Child Health Decisions: The bill rewrites child health supervision rules so that “prevailing medical standards” now mean whatever the DOH says. Insurance must cover the DOH-chosen immunizations at no cost to the family, leaving parents who want a different schedule to pay full price.
  5. Separation of Medicine and State: Standing orders, mandatory insurance coverage with no cost-sharing, pharmacy administration, and legal immunity combine to create a single state-directed pipeline for preventive care.

Department of Health Given Final Authority

The bill makes the Hawaii Department of Health the tie-breaker when national medical groups disagree.

It states that if recommendations from the Advisory Committee on Immunization Practices and the American Academy of Pediatrics differ, “the department of health shall determine which recommendations shall apply.”

It also gives the DOH new power to issue standing orders for medications and immunizations, allowing them to be given without an individual doctor’s prescription.

Legal Protection Tied to Following State Guidance

The immunity language is clear:

“No professional organization or association, health care provider, or health care facility shall subject any person to discipline, suspension, loss of license, loss of privileges, loss of membership, or other penalty for providing clinical preventive services in accordance with recommendations made pursuant to section 321-31.”

Insurance Must Cover DOH-Approved Services at No Cost

For policies issued after January 1, 2027, insurers must provide coverage “without any deductible, copayment, coinsurance, or other cost-sharing requirements” for anything the DOH recommends.

Every Hawaii policyholder will likely pay higher premiums to subsidize the DOH’s choices—while families who want a different schedule get zero coverage and pay 100% out of pocket.

Pharmacies Can Administer Vaccines Under DOH Rules

HB1898 expands who can give vaccines by allowing pharmacists, pharmacy interns, and registered pharmacy technicians to administer them when ordered in line with DOH recommendations or standing orders.

What This Means in a Future Outbreak

If the DOH issues new recommendations during the next public-health emergency, those shots or treatments can be rolled out quickly through pharmacies, must be covered by insurance, and anyone administering them is protected from lawsuits or discipline as long as they followed DOH guidance.

Negligence Exception Exists, But Standard Is Compliance

The bill still allows claims for injury “arising from negligence.”

In practice, however, the legal test will center on whether the provider followed the Department of Health’s recommendations.

Bottom Line

HB 1898 gives the Department of Health the power to decide which preventive medical interventions are covered and protected by law.

It forces insurers to pay for the state’s choices with no patient cost-sharing and removes meaningful accountability for providers who follow those choices.

Hawaii families who want options outside the official schedule will face higher costs and fewer willing providers.

When the state controls the definition of medical truth and shields its enforcers from consequences, bodily autonomy and informed consent become conditional on government approval rather than individual rights.

Maine Builds Rapid Influenza Vaccine Deployment and Tracking System—Pharmacists Granted Full Authority for Statewide Rollout ‘Without a Prescription’


L.D. 2071 requires pharmacists to report each vaccine within 72 hours to a centralized state system, enabling real-time monitoring of vaccination across the population.

Maine lawmakers have passed legislation that fundamentally restructures how influenza vaccines can be deployed across the state—establishing a system capable of rapid, large-scale distribution to the general population without relying on physicians.

The final version of L.D. 2071 gives pharmacists full independent authority to prescribe, dispense, and administer influenza vaccines to individuals as young as 3 years and 6 months old—without a prescription or prior medical approval.

This structure removes physician oversight, concentrates vaccination authority in retail pharmacies, and pairs rapid, population-wide access with centralized state reporting—raising concerns about informed consent, medical autonomy, and the state’s ability to execute a fast, large-scale influenza vaccination campaign if another public health emergency is declared.

As of April 7, 2026, the bill has passed both chambers in identical final form and has been ordered sent to the Governor’s desk for signature.

The bill will take effect 90 days after the Legislature adjourns, which is scheduled for April 15, 2026—meaning the new pharmacist authority would become law on July 14, 2026.

The legislation’s advancement comes amid state, federal, and international influenza outbreak orchestration.

It is sponsored by Democrat Representatives Sally ClucheyPoppy ArfordRyan FecteauKristi MathiesonDaniel Shagoury, and Republican Rep. Amy Arata.

You can contact Governor Janet Mills office here.


Pharmacists Become Frontline Vaccination Authority

Under the amended statute:

“A pharmacist… may prescribe, dispense or administer… all forms of influenza vaccines… to a person 3 years 6 months of age or older without a prescription.”

This language removes the traditional requirement that a physician authorize vaccination—transferring full control over influenza vaccine delivery directly to retail pharmacies.

Pharmacists are no longer limited to administering a doctor’s order.

They can now initiate vaccination themselves.

That shift transforms pharmacies from passive distribution points into independent vaccination hubs capable of operating at scale.

Statewide Retail Network Activated for Mass Deployment

By design, the system leverages the existing pharmacy network as the backbone of vaccine delivery.

Instead of relying on:

  • clinics
  • hospital systems
  • scheduled appointments

The law enables:

  • walk-in access
  • immediate administration
  • decentralized distribution

Pharmacies—already embedded in nearly every community—function as a ready-made infrastructure for rapid statewide rollout.

Influenza Singled Out for Broadest Authority

The legislation treats influenza differently from all other vaccines.

  • Influenza vaccines:
    • pharmacist can prescribe, dispense, and administer
    • applies down to age 3 years 6 months
  • Other vaccines:
    • independent pharmacist authority limited to adults 18+
    • minors require a doctor’s prescription

This makes influenza the only vaccine category granted full pharmacist-controlled access across both adults and young children.

Real-Time State Tracking Built In

The bill also requires that every administered vaccine be reported:

Pharmacists must report vaccine administration to the state immunization information system within 72 hours.

This creates a centralized system capable of:

  • tracking vaccination rates
  • monitoring geographic uptake
  • identifying gaps in coverage

The result is near real-time visibility into how widely vaccines are being administered across the population.

Insurance Language Opens the Door—Without Mandating Coverage

While earlier versions of the bill proposed mandatory no-cost vaccine coverage, the final version stops short of requiring it.

Instead, the amended law clarifies that insurers are authorized to cover vaccines without cost-sharing if they choose, rather than mandating it.

Even without a mandate, the structure aligns financial incentives with expanded access.

What the Structure Reveals

The bill establishes:

  • Immediate, walk-in vaccination access
  • No physician gatekeeping
  • A statewide pharmacy-based delivery network
  • Rapid reporting into a centralized tracking system
  • Inclusion of young children in the rollout model

This represents a complete redesign of how influenza vaccines can be deployed at scale.

Bottom Line

Maine legislators have constructed a system that allows influenza vaccines to be distributed quickly, broadly, and with minimal friction across the entire population.

If activated, the infrastructure enables any individual to walk into a pharmacy, receive an influenza vaccine on the spot, and have that dose logged into a statewide tracking system within days—without ever interacting with a physician.

$2.46 Billion ‘Momnibus’ Bill Targets Pregnant Women for Vaccination—Builds $715 Million Real-Time Surveillance System Activated During Pandemics. THIS IS EXACTLY HOW IT BEGINS GETTING 100% OF THE POPULATION JABBED WITH THEIR EVIL INJECTION. STARTING WITH THE NEWBORNS!


H.R. 7973, with 203 cosponsors, would create a closed-loop federal system to identify pregnant women by race and demographics, boost their vaccination rates, and track them in real time.

Jon Fleetwood

Apr 06, 2026

A federal bill introduced in Congress would create a system where pregnant women are not only targeted for increased vaccination but also tracked through a federally coordinated surveillance network that activates during pandemics.

H.R. 7973—the “Momnibus Act”—authorizes a staggering $2.46 billion overall, with $715 million of that specifically allocated to build this structure: combining mass vaccination initiatives with a real-time data tracking system designed to monitor health status, outcomes, and demographic characteristics during declared public health emergencies.

The bill constructs a pipeline to identify the population, increase medical intervention, and track the results—continuously, at scale, and under federal coordination.

From a health freedom standpoint, this represents a shift away from individual consent-driven care and toward a system where specific populations are identified, targeted, and monitored during crises.

Introduced by Rep. Lauren Underwood—Backed by Industries Positioned to Benefit

The legislation was introduced on March 18, 2026 by U.S. Representative Lauren Underwood (D-IL-14) and immediately routed to multiple House committees, including Energy and Commerce.

It remains at the earliest stage of the legislative process, with no hearings or votes.

Campaign finance data shows support from healthcare systems, insurance networks, and pharmaceutical-aligned interests—industries that would directly benefit from:

  • expanded vaccination programs
  • increased federal funding streams
  • long-term surveillance infrastructure

The same entities positioned to carry out the bill’s mandates are among those funding its sponsor.

You can contact Rep. Underwood here and the rest of the bill’s 203 cosponsors here to voice your opposition to the expansion of federally directed vaccination targeting, real-time health surveillance during public health emergencies, demographic-based population profiling, centralized control over medical data and response, and the erosion of informed consent and individual medical autonomy.

Federal Government Moves to Identify & Increase Vaccination in Targeted Populations

The bill directs federal agencies to “increase vaccination rates of pregnant and postpartum individuals… and their children.”

Funding is explicitly tied to expanding these efforts, with hundreds of millions authorized specifically for awareness and equity campaigns that prioritize populations with “low rates of vaccination” and “racial and ethnic minority groups.”

The federal government is authorized to identify which groups are not complying with recommended vaccination schedules and focus massive resources on increasing uptake in those populations.

That is a shift from informed consent at the individual level to behavioral targeting at the population level.

$715 Million Surveillance & Vaccine Apparatus Designed for Pandemic Activation

Of the bill’s $2.46 billion total authorizations, $715 million goes directly to the combined maternal vaccine push and surveillance system:

  • $190 million for CDC maternal surveillance system, expanded mortality/morbidity tracking, national pregnancy risk monitoring, and NIH emergency research.
  • The remaining hundreds of millions are dedicated to the maternal vaccination awareness and equity campaign (including the updated $73.4 million per year authorization for 2027–2032).

The system will be used for “data collection, surveillance, and research… as a result of public health emergencies and infectious diseases.”

Real-Time Monitoring of Medical Status During Emergencies

The system tracks “diagnostic testing, confirmed cases, hospitalizations, deaths…” with updates required “at least on a monthly basis.”

This creates continuous, rolling surveillance of a defined population during a declared emergency.

In practical terms, once an emergency is declared, the federal system gains ongoing visibility into who is infected, who is hospitalized, and how individuals are progressing.

That is real-time population monitoring tied directly to health status.

Nationwide Data Integration—From Lab to Federal Database

The bill requires “capacity building… to collect and transmit… demographic data” and mandates that laboratories receive “race, ethnicity, pregnancy status… and other demographic data.”

This creates a standardized data pipeline: data originates at testing sites and hospitals, moves through state systems, and is centralized at the federal level.

Mandatory Demographic Profiling of Health Data

All collected data must be categorized by “race, ethnicity, gender, primary language, geography, socioeconomic status.”

Rather than just tracking disease, the bill would allow tracking of mothers who have the disease, where they are, and what demographic group they belong to.

That enables targeted interventions and creates a framework for population-level categorization tied to medical status.

Centralized Data Collection Before Public Release

The bill requires public reporting on the CDC website while stating “all data collected is deidentified.”

The key distinction is timing.

Data is collected in detailed individual form first, then anonymized before public release.

Federal Authority Expands Immediately After Emergency Declaration

Within 30 days of a public health emergency, “the Secretary shall issue guidance.”

This allows federal officials to control how states collect data, categorize individuals, and manage reporting systems.

A Closed-Loop System: Identify, Intervene, Track

The structure of the bill connects three functions into one system:

  • Identify populations through demographic data
  • Increase vaccination rates within those populations
  • Track outcomes during infectious disease events

This creates a feedback loop where data identifies targets, programs drive intervention, surveillance measures compliance and outcomes.

All operating under federal coordination during a public health emergency.

Bottom Line

H.R. 7973 establishes a federally coordinated $715 million system (within a $2.46 billion bill) that:

  • identifies specific populations of pregnant and postpartum women for increased vaccination
  • tracks their medical status in real time during pandemics
  • categorizes individuals by demographic characteristics
  • integrates data across labs, hospitals, and government systems
  • centralizes authority during declared emergencies

The bill lays the groundwork for a model where medical decisions are no longer purely individual—but increasingly shaped by population-level targeting, centralized guidance, and continuous monitoring during crises.

Missouri Senate Passes Bill Blocking WHO, UN, WEF Authority—’No Foreign Laws Act’ Declares Global Bodies Have ‘No Jurisdiction or Power’ in State

Apr 5

Read full story

Maryland Bill Lets Pharmacists Order Vaccines for You—Logging Your Name in State Tracking System Without Any Patient-Request Requirement

Apr 3

Read full story

NIAID/NIH and USDA Fund Bioengineered Chimeric Influenza Viruses Built Using Pandemic H1N1 Components: Journal ‘Science Advances’

Jon Fleetwood

·Read full story

West Virginia Bill Forces Vaccine History Into Every Sudden Death Under 30: HB4915

Jon Fleetwood

Apr 2

Read full story

Illinois Bill Turns Hospitals Into Mass Influenza Shot Intake Points for Every Adult, Mandates Universal Identification and Targeting System

Mar 30

Read full story

WHO Influenza Plan Orchestrates Global mRNA-Based ‘Next-Generation’ Pandemic Vaccine System Through 2050—46 Vaccines Already Underway

Jon Fleetwood

Mar 27

Massachusetts Advances H5N1 Influenza Bird Flu Bill with Quarantine Protocols, Surveillance Grid, and Vaccination Strategies


Lawmakers move avian influenza response infrastructure into study pipeline while preserving full operational framework.

A Massachusetts bill laying out a full-scale response system for H5N1 avian influenza “bird flu” is advancing through the legislature—constructing quarantine protocols, mass surveillance systems, vaccine deployment planning, and statewide clinical trial infrastructure around a single named virus before any declared widespread outbreak.

The move comes as state, federal, and international actors are orchestrating the systems, infrastructure, and response mechanisms surrounding a future bird flu pandemic.

Massachusetts House Bill 2385 (H2385), introduced February 27, 2025 by Representative Leigh Davis (D-3rd Berkshire), does not address general pandemic preparedness.

Instead, it is specifically targeted at H5N1 bird flu, directing the state to build a coordinated response system spanning human, livestock, and wildlife populations under a single-disease framework.

On March 16, 2026, lawmakers moved the bill into a Public Health study order (H5234), advancing the proposal into a formal development phase—preserving the full framework while removing it from an immediate vote.

After sitting untouched for over a year, the bill was suddenly acted on and moved into a study process—signaling it had become important enough to preserve and develop, but not yet ready to pass in its current form.

You can contact Rep. Davis’ office here and the rest of the Massachusetts representatives here to voice your opinion on the bill.


Emergency Bird Flu Powers Activated Up Front

The bill opens with emergency language:

“declared to be an emergency law, necessary for the immediate preservation of the public health.”

This positions the H5N1 response system for rapid activation, not gradual implementation.

Mass Bird Flu Surveillance Across Humans & Animals

The bill directs:

“developing surveillance programs to detect and track outbreaks of H5N1 in wildlife, poultry, dairy cattle and humans”

This creates a multi-species surveillance system focused specifically on bird flu, linking:

  • agricultural environments
  • wildlife reservoirs
  • human cases

into a centralized tracking network.

Quarantine & Vaccine Plans Pre-Built for H5N1

The commission is tasked with designing:

“emergency response plans… including quarantine measures, vaccination strategies”

This establishes predefined intervention mechanisms, including:

  • quarantine and isolation protocols
  • movement restrictions tied to exposure
  • coordinated vaccine deployment strategies

—all built specifically around bird flu response.

Statewide Bird Flu Trials Ready for Rapid Deployment

The bill calls for:

“preparation to launch statewide clinical trials that swiftly evaluate… novel therapeutic approaches”

This enables:

  • rapid testing of treatments during an H5N1 event
  • deployment of experimental or emerging interventions
  • statewide scaling of trials

Farm Testing Network Expands Bird Flu Detection

The legislation includes:

“production of self-administered swabs… distributed to farms… allowing workers to… screen themselves”

This creates a continuous testing system tied directly to bird flu monitoring in:

  • farms
  • livestock environments
  • worker populations

Drug Stockpiles Expand as Bird Flu Mutation Expected

The bill directs:

“shoring up of stockpiles… beyond Tamiflu… guard against viruses mutating”

This anticipates:

  • mutation of H5N1
  • purported need for expanded pharmaceutical reserves
  • long-term treatment preparedness tied to bird flu

Private Funding Flows Into Bird Flu Response System

The commission is authorized to receive:

“funds from public and private sources such as gifts, grants and donations.”

This integrates:

  • private funding sources
  • external organizations
  • non-government actors

into state bird flu response infrastructure.

Centralized Control System Coordinates Bird Flu Response

The bill mandates:

“coordinating efforts among government agencies… public health entities”

This establishes a centralized response model specifically for bird flu, aligning:

  • public health agencies
  • agriculture
  • research institutions

Bill Quietly Advanced Into Study Pipeline Without Vote

The proposal remains active:

  • Folded into study order H5234
  • Discharged from Public Health Committee
  • Transferred to the House Rules Committee

This keeps the full H5N1-focused framework moving through the legislative pipeline, positioning it for future action.

Bottom Line

H2385 is not a general preparedness bill.

It builds a targeted operational framework around avian influenza (H5N1) specifically.

The bill establishes:

  • A bird flu surveillance grid across humans, livestock, and wildlife
  • Predefined quarantine and vaccination protocols tied to H5N1
  • A statewide clinical trial system ready for deployment
  • A continuous testing pipeline in agricultural settings
  • Expanded drug stockpiling anticipating mutation
  • A public-private funding structure embedded in response planning
  • A centralized command system for coordinated bird flu response

Lawmakers have now moved this framework into a formal study process—keeping it active and positioning it for future rollout.

China Conducts mRNA Influenza Bird Flu Vaccine Trials in Dairy Cows: Journal ‘Research’


Government preparation for large-scale mRNA vaccination of livestock.

Chinese government–funded researchers have confirmed that they tested an mRNA bird flu vaccine in lactating dairy cows, injecting milk-producing livestock with an mRNA–lipid nanoparticle formulation and then deliberately exposing the animals to live H5N1 influenza virus inside high-containment laboratories.

The peer-reviewed study published on Monday, in the journal Research, is titled “Protective Efficacy of a Hemagglutinin-Based mRNA Vaccine Against H5N1 Influenza Virus Challenge in Lactating Dairy Cows.”

The experiment signals that governments are actively preparing mRNA platforms for potential large-scale use in livestock populations, extending mRNA deployment beyond humans and into the food supply.


mRNA Vaccine Administered to Food-Producing Animals

According to the study, researchers injected an mRNA vaccine into lactating Holstein dairy cows, meaning animals actively producing milk.

The authors write:

“Six healthy lactating dairy cows were intramuscularly immunized with 500 μg of the mRNA vaccine twice, with a 3-week interval between doses.”

The animals were sourced from an external farm:

“Lactating Holstein cows, 3 to 5 years of age, obtained from a local dairy farm, were used in the challenge experiment.”

The vaccine was an mRNA–lipid nanoparticle (mRNA–LNP) formulation encoding the hemagglutinin protein of an avian influenza virus:

“We developed a monovalent, cattle-codon-optimized mRNA–LNP vaccine encoding the HA protein.”

Deliberate Infection with H5N1 Pathogen

After receiving the mRNA injections, both vaccinated and unvaccinated cows were moved into animal biosafety level 3+ (ABSL-3+) laboratories and deliberately infected with a purportedly live H5N1 influenza virus.

The paper states:

“3 vaccinated and 3 unvaccinated lactating dairy cows were transferred into the animal biosafety level 3+ (ABSL-3+) facility for the challenge study.”

The virus was said to be administered through multiple routes, including direct injection into the mammary glands:

“All cows received a DC/24 virus challenge administered via both the intranasal and intramammary routes.”

The authors further specify:

“3 doses were directly inoculated into separate mammary quarters via the teat.”

High-Containment Facilities & Lab-Generated Viruses

All work involving the pathogen was performed inside Chinese state-authorized high-containment laboratories.

The methods section states:

“The procedures involving live HPAI viruses were performed within certified BSL-3 and ABSL-3+ laboratories at the Harbin Veterinary Research Institute (HVRI), Chinese Academy of Agricultural Sciences (CAAS).”

The H5N1 viruses used were not simple field samples but laboratory-generated strains.

The authors cite a prior peer-reviewed study for the virus’s creation and laboratory handling methods, rather than detailing the generation process in this paper.

“The challenge dairy cow H5N1 virus (DC/24)… was generated as previously described.”

Chinese Government Funding

The study was funded entirely by Chinese state and government research programs.

The funding disclosure reads:

“This research was funded by the National Key Research and Development Program of China… the National Natural Science Foundation of China… the Innovation Program of the CAAS… the natural science foundation of Heilongjiang Province… [and] the Central Public Interest Scientific Institution Basal Research Fund.”

All authors are affiliated with Chinese government research institutes or state-linked laboratories, including the Chinese Academy of Agricultural Sciences and China’s National High Containment Laboratory for Animal Disease Control and Prevention.

Bottom Line

The paper confirms that China is now testing mRNA vaccine platforms directly in livestock, including milk-producing animals, using live avian influenza viruses under high-containment laboratory conditions.

The study documents the use of modern mRNA technology not only in humans or laboratory animals, but in food-supply species that interface directly with agriculture, trade, and public health systems.

Canada Builds Live SARS-CoV-2 Viruses From Computer Code Alone That ‘Can Be Used For Gain-of-Function Research’: Journal ‘Viruses’


A closed pandemic loop of digital design, synthetic GOF viruses, and government-controlled verification.

A new peer-reviewed study published in the journal Viruses says that publicly funded Canadian laboratories digitally designed full-length SARS-CoV-2 genomes, chemically synthesized them using commercial services, and generated live, replication-competent coronaviruses without starting from a natural virus sample.

The paper, titled “Developing Synthetic Full-Length SARS-CoV-2 cDNAs and Reporter Viruses for High-Throughput Antiviral Drug Screening,” documents the alleged creation of infectious Delta and Omicron SARS-CoV-2 viruses from computer-designed genetic sequences alone.

Coming in the wake of the COVID-19 pandemic—which killed millions of people worldwide and was linked by multiple intelligence agencies to laboratory research—the study raises national security concerns about the ability of government-funded institutions to create replication-competent pandemic viruses from digital sequence data alone, using commercial infrastructure with limited public oversight.

In light of these capabilities, the study also raises the possibility that governments could define, simulate, and respond to a biological threat almost entirely within digital and laboratory frameworks—leaving the public reliant on official interpretation rather than independently observable evidence.


Viruses Built from Computer Code Alone

The authors state that they did not rely on physical viral isolates to create the viruses.

Instead, they used commercial DNA synthesis services to generate the entire coronavirus genome:

“We opted to use cDNA chemical synthesis services to generate full-length wild-type and reporter Delta and Omicron clones.”

They further explain:

“DNA synthesis is a viable method to rapidly generate coronavirus cDNAs and recombinant viruses.”

Those synthesized genomes were then said to be used to generate live viruses:

“Clone-derived Delta and Omicron wild-type and reporter viruses were successfully rescued and showed replication kinetics comparable to patient-derived isolates.”

The study claims that the resulting viruses were infectious and capable of sustained replication in cell culture.

The paper emphasizes that the same system can be used to generate new viral variants based solely on sequence data:

“DNA synthesis is a viable and rapid option to generate reverse genetic systems for wild-type and reporter viruses using sequence information alone.”

Acknowledged Gain-of-Function Capability

In the Discussion section, the authors explicitly acknowledge that the methodology they used qualifies as gain-of-function (GOF) capable research:

“It is important to acknowledge that the novel approach described in this study—generating replication-competent viruses from synthetic DNA while introducing heterogeneous gene functions—can be used for ‘gain-of-function’ research.”

Where the Viruses Were Said to Be Created

All work involving purportedly live SARS-CoV-2 was conducted in Canada at a high-containment facility:

“All the experiments involving infectious SARS-CoV-2 viruses were conducted at VIDO-InterVac in an approved Biosafety containment level 3 (BSL3) laboratory.”

VIDO-InterVac is part of the University of Saskatchewan, which is a central institutional hub for the research described in the paper.

Author Affiliations

The authors are affiliated with multiple Canadian institutions, including:

  • University of Saskatchewan (Department of Biochemistry, Microbiology, and Immunology; Vaccine and Infectious Disease Organization),
  • University of Alberta (Department of Cell Biology; Department of Medical Microbiology & Immunology; Li Ka Shing Institute of Virology),
  • Sunnybrook Research Institute (Toronto),
  • University of Toronto (Department of Laboratory Medicine and Pathobiology).

Public Funding Sources

The research was funded entirely through public Canadian funding, according to the paper’s funding disclosure:

“This research was funded by the Canadian Institutes of Health Research (CIHR)-funded Coronavirus Variants Rapid Response Network (CoVaRR-Net)… CIHR Operating COVID-19 Rapid Research Funding Opportunity—Therapeutics… and NSERC.”

Additional operational support came from:

“The Government of Saskatchewan… the Government of Canada through Prairies Economic Development Canada… and the Canada Foundation for Innovation Major Science Initiatives for its CL3 facility.”

What the Paper Establishes

The study documents, in the authors’ words, that:

  • Full-length SARS-CoV-2 genomes were digitally designed
  • Those genomes were chemically synthesized
  • Live, replication-competent coronaviruses were said to be generated from that synthetic DNA
  • The method is acknowledged to be usable for gain-of-function research
  • The work was publicly funded and conducted in Canadian government-supported laboratories

These facts are stated directly in the paper and do not rely on inference, speculation, or external interpretation.

Bottom Line

The new Viruses paper reveals that governments claim to possess the technical ability to define a virus digitally, synthesize it physically, and validate its behavior entirely within controlled laboratory systems—allowing modern pandemic response to operate almost entirely inside digital, synthetic, and laboratory environments.

That convergence raises unresolved questions about national security, transparency, independent verification, and how much trust the public is asked to place in closed scientific and governmental frameworks when responding to future biological threats.

The study aligns with earlier FOIA-released DARPA documents showing that U.S. biodefense systems were already built to synthesize viruses and manufacture mRNA countermeasures from sequence data alone, placing the Canadian work within a broader pre-existing digital pandemic infrastructure.

Trump Admin Keeps Ties to WHO Influenza System as U.S. Funds Bird Flu Gain-of-Function and Mass Vaccine Programs


Despite claiming to have withdrawn from the international organization.

Despite claiming to have formally withdrawn from the World Health Organization (WHO), the Trump administration has confirmed it is still in active discussions with the agency about participating in next year’s global influenza vaccine strain-selection process—at the same time the U.S. government is funding influenza bird flu gain-of-function research and a $500 million influenza vaccine initiative.

On January 22, the U.S. Department of Health and Human Services (HHS) announced that the United States had completed its withdrawal from the WHO, apparently ending all funding, recalling U.S. personnel, and terminating participation in WHO committees, governance bodies, and technical working groups.

During the same briefing, administration officials acknowledged that influenza remains an open channel for engagement.

Per CNN’s Thursday report:

“HHS left the door open to some continued collaboration, however. Asked if the US would participate in an upcoming WHO-led meeting to decide the composition of next year’s flu vaccines, the administration said conversations about that are still ongoing.”

The statement was made during a call with reporters following the withdrawal announcement.

This places influenza in a separate policy category—one where U.S. withdrawal exists on paper, but coordination with the same international decision system continues.

It raises questions about who is actually setting U.S. influenza policy, and why the one disease tied to global strain forecasting, pandemic modeling, and mass countermeasure production remains exempt from the break.

WHO Exit With Influenza Carve-Out

HHS stated the U.S. has:

  • Terminated all WHO funding
  • Recalled all personnel and contractors
  • Ceased participation in WHO technical working groups and governance bodies

Yet the administration declined to rule out involvement in the WHO’s influenza strain-selection process, which determines the purported viral lineages used in seasonal vaccines worldwide and shapes pharmaceutical manufacturing timelines.

Domestic Influenza Programs Continue to Expand

While negotiating ongoing coordination with the WHO, the federal government is simultaneously expanding influenza and bird flu research and vaccine programs inside the United States.

In 2025, HHS launched a $500 million federal influenza vaccine initiative described as a “gold standard” program designed to accelerate strain updates, enable rapid manufacturing, and support pre-pandemic deployment.

Federal agencies including the NIH, NIAID, USDA, and the Department of Defense continue funding laboratory research on avian and human influenza viruses that deliberately alter viral properties for study, including:

  • receptor binding changes,
  • mammalian transmissibility modeling,
  • chimeric viral backbones,
  • immune escape features.

These experiments are described in peer-reviewed publications and supported through federal research grants and biodefense contracting mechanisms.

U.S. agencies are also funding H5N1 bird flu vaccine platforms using reverse-genetics systems, chimeric viral constructs, and self-amplifying RNA technologies intended for pandemic countermeasure development.

Integrated Influenza Infrastructure

The WHO coordinates global influenza surveillance and strain forecasting.

The U.S. continues negotiating technical access to that system.

Federal agencies fund laboratory modification of influenza viruses and parallel vaccine platforms.

Pharmaceutical manufacturing and preparedness planning rely on the same surveillance and strain data.

Taken together, these disclosures show that despite the publicized WHO withdrawal, the United States remains functionally embedded in the WHO-centered influenza system—where global strain selection, federally funded virus engineering, and government-backed vaccine platforms converge inside the same international pandemic planning architecture.

Jan 23

Read full story

Bird Flu Takes Central Role in Trump Admin’s New $500 Million ‘Next-Generation’ Pandemic Vaccine Project

May 2, 2025

Read full story

NIAID Director Holds Patent for Bird Flu Pandemic Vaccine—as His Agency Creates Frankenstein Bird Flu Viruses in the Lab

October 10, 2025

Read full story

Trump’s CDC, FDA ‘Actively Participating’ in WHO Bird Flu Seminar Despite Executive Order to Withdraw U.S. from International Organization: STAT

February 25, 2025

Read full story

NIAID, DARPA, Bill Gates Intentionally Infect 80 Americans With Lab-Made Pandemic Influenza Virus: HHS Study

October 13, 2025

Read full story

U.S. Military Funds Intranasal Spray Self-Replicating sa-mRNA H5N1 Bird Flu Vaccine Built From Chimeric Viral Constructs: Journal ‘Nature Communications’

Jan 15

Read full story

WHO Vows ‘There Will Be Influenza Pandemics in the Future’

Jan 22

Read full story

WHO Instructs Governments to Track Online Anti-Vaccine Messaging in Real Time with AI: Journal ‘Vaccines’

December 29, 2025

Read full story

WHO Demands 90,000 Influenza and COVID PCR Tests Per Month Worldwide, Spanning 153 Labs in 131 Countries, Including U.S. CDC

December 23, 2025

Read full story

How the WHO Dictated the COVID-19 Pandemic—And How It’s Already Dictating the Coming Bird Flu Pandemic

December 10, 2025

Read full story

‘All Governance Functions Assumed by a Single Entity’: WHO-Backed Influenza Framework Outlines Command Merger During Next Pandemic

December 9, 2025

Read full story

WHO Rolls Out ‘Future’ COVID Pandemic Plan Using U.S. Labs for ‘Global Sentinel Surveillance’—Even After Trump Ordered Withdrawal

December 3, 2025

Read full story

WHO–Gates Blueprint for Global Digital ID, AI-Driven Surveillance, and Life-Long Vaccine Tracking for Every Person

December 2, 2025

Read full story

WHO Deploys National Pandemic Influenza Surveillance Grid in Egypt—270 Officers Trained for Real-Time Monitoring Across 30 Sentinel Sites

November 24, 2025

Read full story

WHO, CDC, Gates, and Oxford Were Used to Test Public ‘Compliance’ Strategies for ‘Lower-Quality Vaccines’ Before Any COVID-19 Jabs Existed: ‘PLOS Glob Public Health’ Journal

November 23, 2025

Read full story

WHO Builds International Pandemic Command System Through New Pathogen-Sharing Agreement

November 10, 2025

Read full story

*Articles credit Jon Fleetwood

NIAID Funds Gain-of-Function Study Engineering Novel Influenza Viruses With New Mammalian Pathogenic and Host-Entry Functions: Journal ‘Emerging Microbes & Infections’


Despite claims the U.S. has stopped bankrolling gain-of-function experiments.

A new peer-reviewed study published this week states that federally funded researchers genetically engineered viruses that gained biological functions not present in any naturally occurring strain, including new host-entry mechanisms, cross-species antigen display, and mammalian lethality.

In multiple cases, viral surface proteins from one species and virus family were deliberately inserted into the genetic backbone of an entirely different virus, creating laboratory chimeras that bridge species and viral lineages that do not naturally mix.

The paper, “Immunogenicity and Efficacy of a Rabies-Based Vaccine against Highly Pathogenic Influenza H5N1 Virus,” appears in Emerging Microbes & Infections.

The study documents three distinct categories of functional gain:

  1. transfer of influenza entry machinery into foreign viral backbones,
  2. reprogramming of rabies virus to perform influenza functions, and
  3. creation of new influenza chimeras that are lethal in mammals.

(Editor’s note: This article makes no claims about virology and/or terrain theory. It is reporting what NIAID-funded scientists claim to be doing with American taxdollars.)

Funding & Research Sites

The authors state:

“This study was supported by… the Center for Research on Influenza Pathogenesis and Transmission (CRIPT), one of the National Institute of Allergy and Infectious Diseases (NIAID) funded Centers of Excellence for Influenza Research and Response (CEIRR; contract # 75N93021C00014), and by NIAID contract SEM-CIVIC (contract number 75N93019C00051).”

NIAD is under the control of Director Jeffery Taubenberger, who is directing U.S. taxdollars toward influenza gain-of-function experiments while holding a patent for an influenza vaccine at the center of the Trump administrations $500 million influenza vaccine program.

This raises national security and conflict of interest concerns, as it represents the simultaneous creation of a lucrative problem and solution.

NIAD is under the authority of U.S. Health and Human Services (HHS), which is led by Robert F. Kennedy Jr.

Animal experiments were approved under:

“the Institutional Animal Care and Use Committee (IACUC) of Thomas Jefferson University (TJU).”

Influenza Host-Entry Functions Transferred Into a Different Virus

The authors state that they created a vesicular stomatitis virus whose native entry protein was replaced with influenza H5:

“VSV∆G-H5-GFP encoding either the clade 1 H5 (A/Viet Nam/1203/2004(H5N1) or the circulating clade 2.3.4.4b cow was generated as described.”

This describes a virus that now uses influenza hemagglutinin to enter host cells—a function VSV does not naturally possess.

It also represents a direct cross-species and cross-virus transfer of host-entry machinery, merging an avian influenza protein with a livestock-associated strain and a human-infecting viral backbone in a single engineered system.

Rabies Virus Reprogrammed to Display & Deliver Influenza Antigen

The study confirms that a rabies virus was engineered to express influenza H5:

“We developed a rabies virus-based H5 vaccine (RABV-H5) by insertion of a synthetic full-length codon-optimized HA ORF of the Influenza virus A/Vietnam 1203/2004(H5N1) into the BNSP333 rabies vaccine vector between the N and P genes.”

The authors further state:

“Presenting both RABV-G and the antigen of choice on the surface.”

This confirms that a neurotropic virus was genetically modified to perform a new influenza-specific function.

The lab construct combines a mammalian neurotropic virus with an avian influenza surface antigen, creating a synthetic cross-species hybrid that does not exist in nature.

Creation of Novel Influenza Viruses That Did Not Exist in Nature

The paper says that new influenza viruses were constructed by genome segment replacement:

“PR8-H5N1, a recombinant Puerto-Rico 8 influenza A virus (A/PR8) in which the HA and NA genomic segments have been replaced with the respective segments of H5N1.”

A second engineered virus is identified:

“Influenza virus A/PR8-H5N1 bovine/Ohio/439/2024 (2024).”

These viruses did not exist prior to laboratory construction.

Engineered Viruses Demonstrated Mammalian Pathogenicity

The authors report intranasal infection of mice with the engineered viruses:

“On days 104 or 150, mice were challenged by IN instillation with 0.05 ml of either 1E5 TCID50 of Influenza A/PR8-H5N1 (Viet Nam 1203 or Cow) or with 100 pfu of HPAI-H5N1 Viet Nam 1203 (2004) diluted in PBS+1% heat-inactivated FBS.”

They further confirm the dose was lethal:

“[O]n day 104 were challenged by IN instillation with a 1E5 pfu lethal dose of A/PR8-H5N1 Viet Nam 1203 virus (>100LD50).”

The paper documents viral replication in lungs:

“While unvaccinated mice had about 1E6 TCID50/ml of replicating virus in the lungs.”

And describes lung pathology:

“Severe and chronic bronchiolocentric infection with bronchiolar and peribronchiolar infiltration of lymphocytes, associated with interstitial pneumonitis and expanded alveolar wall due to edema and inflammation.”

Bottom Line

The new study makes clear that gain-of-function virus creation is allegedly still being carried out with U.S. taxpayer dollars, despite the national security and biosafety risks such work poses to the very population funding it.

Congress, the White House, the Department of Energy, the FBI, the CIA, and Germany’s Federal Intelligence Service (BND) have confirmed that the COVID-19 pandemic was likely the result of lab-engineered pathogen manipulation.

Why does the U.S. continue to fund the same experiments that are said to have caused the last pandemic?

June 19, 2025

Read full story

NIAID Director Holds Patent for Bird Flu Pandemic Vaccine—as His Agency Creates Frankenstein Bird Flu Viruses in the Lab

October 10, 2025

Read full story

Bird Flu Takes Central Role in Trump Admin’s New $500 Million ‘Next-Generation’ Pandemic Vaccine Project

May 2, 2025

Read full story

USDA–Iowa State University Lab-Engineer New Chimeric Bird Flu Viruses That Bind to Human Breast Tissue: ‘Journal of Dairy Science’

November 30, 2025

Read full story

USDA–NIH–University of Georgia–Mount Sinai Team Aerosolizes Lab-Engineered ‘Chimeric’ Influenza Frankenviruses: Journal ‘npj Vaccines’

November 28, 2025

Read full story

NIAID Funds Creation of Chimeric H5N1 Bird Flu Viruses With Modified Cleavage Sites and Enhanced Mammalian-Cell Expression: ‘npj Vaccines’

November 29, 2025

Read full story

Trump Admin Doubles Down on EO Exemptions for Gain-of-Function Experiments: Journal ‘Nature Medicine’

Jan 17

Read full story

WHO Vows ‘There Will Be Influenza Pandemics in the Future’

Jan 22

Read full story

‘Critical Loophole’ in U.S. Biosecurity Rules Allows Legal Assembly of 1918 Spanish Flu Pandemic Virus DNA: Journal ‘Nature Communications’

Jan 16

Read full story

U.S. Military Funds Intranasal Spray Self-Replicating sa-mRNA H5N1 Bird Flu Vaccine Built From Chimeric Viral Constructs: Journal ‘Nature Communications’

Jan 15

Read full story

Portugal Runs H5N1 Bird Flu Outbreak Simulation—Echoing Pre-COVID Pandemic Exercises

Jan 13

Read full story

DARPA Uses AI to Push Viral Pandemic Outbreak Modeling From Weeks to Days

Jan 9

Read full story

Bill Gates’ CEPI Revives Moderna mRNA Bird Flu Vaccine Development With $54M Investment After HHS Terminated Funding

December 19, 2025

Read full story

Saudi Arabia Bets on 2026 Bird Flu Pandemic, Ramps Up Domestic Vaccine Production Amid International H5N1 Gain-of-Function Fears

October 30, 2025

Read full story

*Article credits Jon Fleetwood